Dyne Therapeutics (NYSE:DYN) Upgraded to “Hold” at StockNews.com

Dyne Therapeutics (NYSE:DYNGet Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report issued on Sunday.

Dyne Therapeutics Price Performance

Shares of NYSE:DYN opened at $13.70 on Friday. Dyne Therapeutics has a 52 week low of $4.30 and a 52 week high of $15.63. The stock has a market capitalization of $798.86 million, a P/E ratio of -4.11 and a beta of 0.23.

Dyne Therapeutics Company Profile

(Get Rating)

Dyne Therapeutics, Inc operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United States.

Recommended Stories

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.